SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing extreme volatility and a sharp downward trend, fueled by investor panic over cyclical memory demand, cooling enthusiasm for the AI trade, and negative sentiment surrounding peer earnings in the sector. The community is deeply polarized, with many retail investors expressing frustration over aggressive algorithmic trading and margin calls, while others debate whether this represents a fundamental structural breakdown or a buying opportunity following a massive drawdown from recent highs.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing extreme volatility as the broader memory sector reacts to an earnings miss from South Korean competitor SK Hynix, triggering a ripple effect across chip stocks. The community is sharply divided between those viewing the pullback as a manipulated shakeout of retail investors by market makers and those fearing the start of a deeper cyclical downturn in AI-related hardware demand.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is experiencing extreme volatility following a quarterly earnings report that showed record-breaking growth but missed aggressive analyst estimates, sparking intense debate over whether the sell-off is a result of valuation concerns or institutional manipulation. The community is deeply divided, with many traders frustrated by the stock's impact on the broader semiconductor sector and local market instability, while others maintain that the underlying fundamentals remain strong for long-term AI-driven demand.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing extreme volatility and selling pressure as investors digest an industry-wide semiconductor slump, exacerbated by geopolitical tensions and major drops in the South Korean tech sector. The community is deeply polarized, with many retail traders panic-selling or lamenting significant losses while others attempt to bottom-fish, debating whether the sector's long-term AI-driven potential remains intact or if this signifies a fundamental bubble collapse.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently experiencing high volatility driven by a broader semiconductor selloff and intense investor debate over whether the massive capital expenditure fueling AI infrastructure will generate sustainable long-term returns. While some in the community are panic-selling and calling for further corrections, others are actively treating the pullback as a buying opportunity, pointing to recent partnerships and sustained demand for AI-compute capacity as evidence that the company's growth story remains intact.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is hitting record valuations as investors pivot away from AI-infrastructure-heavy tech stocks in favor of its disciplined capital spending and massive services revenue. The community remains deeply divided, with bulls highlighting the stock's stability as a market safe haven, while bears argue the valuation is detached from fundamentals and overdue for a significant correction.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors brace for high-stakes earnings paired with a critical interest rate decision, leading to intense debate over the stock's direction. Community sentiment is deeply divided, with many traders anticipating a volatile reaction based on management's forward guidance and the ongoing impact of macroeconomic headwinds.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending amid significant volatility driven by semiconductor sector weakness following poor earnings in South Korea, alongside rising geopolitical tensions and uncertainty ahead of key central bank policy decisions. The community is actively debating the sustainability of AI-related growth and whether the recent price swings signal a deeper technical correction or a temporary pullback within a broader uptrend.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh significant volatility in global semiconductor markets against robust AI infrastructure demand, with community discourse divided between concerns over circular financing and institutional buying at key support levels.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing intense volatility after FDA briefing documents cast doubt on the trial's statistical validity, triggering a sharp decline in the share price ahead of an upcoming Advisory Committee meeting. The community is sharply divided, with bulls arguing the data demonstrates durable efficacy in treating Duchenne muscular dystrophy and suggesting the FDA's critique relies on obsolete analysis, while bears point to the potential for regulatory rejection due to the cited statistical discrepancies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial...

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Equity

Chardan analyst Keay Nakae raised the firm's price target on Arrowhead to $115 from $90 and keeps a Buy rating on the shares.

ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval

The biotech firm reported positive topline results from two Phase 3 studies evaluating its hypertriglyceridemia therapy.


Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG), a condition that significantly increases the risk of acute pancreatitis (AP), which is...

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.Webcast and Conference Call DetailsInvestors may access a live...

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Goldman Sachs upped its price target on Ionis to $75 and maintained a ‘Neutral’ rating on the shares. 


Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial...

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the companys proprietary Targeted RNAi Molecule (TRiM) platform. Each webinar in the...

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3, 2026, 8:10 am EDT Goldman Sachs 47th Annual Global...

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$85.78
Prev Close	$85.53
Open	$86.31
Dividend Yield	0.00%
50-Day Moving Average	$78.09
Beta	1.65
Avg. Volume	2.6M
PE Ratio	-39.93

52-Week High	$95.49
52-Week Low	$15.01
Market Capitalization	$12.05B
EPS (Annual)	-$0.0122
Price to Book	19.64
Revenue Per Employee	$1.17M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ARWRArrowhead Pharmaceuticals Inc.

Latest ARWR News